Cardiovascular Disease
30 videos · last 6 months shuffled daily, then older videos newest first
▶
54:42 ICECAP: The Results
Scott Berry discusses ICECAP trial results with four Principal Investigators. The panel dissects the ICECAP trial’s multi-arm Bayesian adaptive design, response-adaptive randomization, and population-level approach to cooling duration after out-of-hospital cardiac arrest.
▶
1:15 CARES Phase III Trials of Anselamimab in AL Amyloidosis
Giada Bianchi, MD, of Brigham and Women's Hospital and Dana-Farber discusses the Phase III CARES studies of anselamimab in newly diagnosed AL amyloidosis, which missed the primary endpoint but showed a mortality benefit in kappa disease, at SOHO 2026.
▶
59:46 Cardiac Effort: A Digital Endpoint Beyond the 6-Minute Walk
A Digital Medicine Society webinar presents Cardiac Effort, a digital biomarker combining continuous ECG and accelerometry as heartbeats per distance walked, as an alternative to the 6-Minute Walk Test endpoint in cardiovascular trials.
▶
1:02:05 ESC 2026 Roundtable: Antiplatelet, STEMI and TAVI Trials
Chair Mirvat Alasnag and faculty including Roxana Mehran, C. Michael Gibson and Marco Valgimigli discuss which ESC Congress 2026 antiplatelet, STEMI and TAVI trials are most likely to influence practice, and their limitations, for Radcliffe Cardiology.
▶
11:25 HELIOS-B: Vutrisiran With and Without Tafamidis in ATTR-CM
Yasuhiro Hamatani, MD, PhD, discusses a HELIOS-B analysis in transthyretin amyloid cardiomyopathy finding vutrisiran's effects on mortality and cardiovascular events consistent in direction with or without baseline tafamidis, for JACC.
▶
4:37 CoCAP: Graft Patency With DAPT vs Aspirin After CABG
Dr Jonas Holm of University Hospital Linköping discusses the CoCAP study, which used CT angiography to compare graft patency after bypass surgery in TACSI trial patients given ticagrelor-based DAPT or aspirin alone, at ESC Congress 2026.
▶
5:43 ASPIRED: Ambulatory ECG Monitoring in Unexplained Syncope
Matthew Reed, MD, and C. Michael Gibson, MD, discuss ASPIRED, a multi-centre open-label randomised trial of immediate enhanced ambulatory ECG monitoring versus standard monitoring in patients with acute unexplained syncope.
▶
47:48 OPTIMA-AF: One Month of Dual Therapy After PCI in AF
Yohei Sotomi, MD, PhD, of The University of Osaka and Ken Kozuma, MD, PhD, of Teikyo University discuss the OPTIMA-AF trial of shortened antithrombotic therapy after PCI in atrial fibrillation, from enrollment challenges to publication in The Lancet.
▶
9:25 Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3
Diana Isaacs, PharmD, and Natalie Bellini, DNP, on topline Phase 3 TRIUMPH-3 results for retatrutide, a triple agonist, in adults with obesity.
▶
58:24 Analytical Mass Spectrometry Workflow for VAMS and Its Applications in Cardiology and Beyond
Jenny Van Eyk, Professor of Cardiology at Cedars-Sinai, on a mass spectrometry proteomic workflow for volumetric absorptive microsampling, moderated by Neil Spooner of the Patient Centric Sampling Interest Group.
▶
54:51 Deborah Morley, RQM+, on Cardiovascular Device Development
Deborah Morley, Director, Cardiovascular Strategy and Delivery at RQM+, draws on her work with Class III implantable cardiovascular devices such as LVADs to discuss device development, regulatory approval and clinical adoption, for bioaccess.
▶
18:27 The CKM Score in Clinical Trial Design
Dr. Carine Hamo, Dr. Ankeet Bhatt and Dr. Javed Butler discuss the CKM score and the quantitative methods beginning to change how clinical trials are designed and conducted, on the CardioPod podcast.
▶
47:31 ESC 2026 Trials to Watch with Prof Van Mieghem & Dr Bertrand
Prof Nicolas Van Mieghem and Dr Philippe Bertrand discuss the Hot Line trials at ESC Congress 2026 they believe could most influence cardiovascular practice, from ACACIA-HCM and STAREE to LIBREXIA ACS and TRIC-I-HF.
▶
5:40 What Is Recurrent Pericarditis? A Rare Inflammatory Heart Disease Explained
Cardiol Therapeutics explains recurrent pericarditis and describes its oral therapy CardiolRx, now in the pivotal Phase III MAVERIC trial with results expected in early 2027.
▶
2:45 ATTRibute-CM: Acoramidis Survival Over 54 Months
Kevin Alexander, MD, and C. Michael Gibson, MD, discuss interim findings from ATTRibute-CM and its open-label extension on survival with acoramidis over 54 months in variant transthyretin amyloid cardiomyopathy, including p.V142I.
▶
1:56 FDA Approval of a Duchenne Gene Therapy Developed at Nationwide
Nationwide Children's Hospital reports FDA approval of a gene therapy for Duchenne muscular dystrophy developed there, with principal investigator Jerry Mendell, MD, describing the single-infusion clinical trial in boys with DMD.
▶
8:13 Radcliffe Cardiology Looks at Results of the CRISPR-Cas9 First-in-Human Clinical Trial
A clinical trial of an investigational drug NTLA-2001 was tested recently in participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM) or wild type cardiomyopathy (ATTRwt-CM), a type of serious heart disease.
▶
2:10 Mavacamten Shows 80% Efficacy Against Hypertrophic Cardiomyopathy in Clinical Trial
Cleveland Clinic looks at clinical trials of a new drug for Hypertrophic Cardiomyopathy called mavacamten that was tested as part of the VALOR-HCM clinical trial.
▶
44:27 Knowledge Graphs and GenAI in Clinical Trial Programming
Karl Brand of Bayer, in a Verisian presentation, discusses the challenges of clinical trial data programming and how knowledge graphs and large language models could speed regulatory submissions.
▶
1:00:00 Arterial Health Biomarkers in Drug Development
A Cardiex webinar explains how a wearable device measuring central blood pressure and pulse wave analysis can provide arterial-stiffness biomarkers and remote real-world evidence for drug development and cardiovascular trials.
▶
3:12 ARCHER Phase II Results: A New Hope For Heart Disease
Cardiol Therapeutics presents results from ARCHER, its global Phase 2 trial in acute myocarditis, which it reports reduced left ventricular mass; there are no FDA-approved treatments for the condition.
▶
5:53 Roche's Head of Cardiovascular Disease Dissects GLP-1 Drug Trial Results
Manu Chakravarthy, Roche SVP and global head of cardiovascular disease, discusses the company's recent weight-loss drug trial results on CNBC's Fast Money.
▶
15:46 The Future of Heart Failure Clinical Trials in Canada
Dr. Justin Ezekowitz, Director of Cardiovascular Research and Co-Director of the Canadian VIGOUR Centre at the University of Alberta, discusses the future of heart failure clinical trials in Canada at the 2024 Ted Rogers Centre Heart Failure Symposium.
▶
48:20 Clinical and Operational Considerations for QT Evaluation
Borje Darpo of Clario and Justin Couture of Dr. Vince Clinical Research cover QT evaluation under the revised ICH E14/S7B guidance, concentration-QTc analysis and site-level practice for cardiac safety in early-phase studies.